Johnson & Johnson Reports Positive Topline Results for Nipocalimab From a Phase 3 Pivotal Study in Generalized Myasthenia Gravis (gMG) and a Phase 2 Study in Sj ögren ' s Disease (SjD)

SPRING HOUSE, Pa., Feb. 5, 2024 /PRNewswire/ -- Johnson& Johnson today announced topline results from the pivotal Phase 3 VIVACITY study of nipocalimab in adults living with generalized myasthenia gravis (gMG) as well as the Phase 2 DAHLIAS...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials